• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Dr Shore as the principal investigator


    Dr. Shore, as the principal investigator of this trial, was involved in study design, interpreted the data, and reviewed the drafts of the manuscript. Dr. Parente was responsible of the project conceptualization and was involved in the clinical trial study design. Moreover, he was the project leader for the development of leuprolide acetate formulation. Ms. Sanahuja and Dr. Guerrero managed the project at the sponsors site; in addition, they contributed, together with Dr. Gamb├║s and Dr. Parente, to analysing the data, writing the
    Clinical Therapeutics
    manuscript, and creating figures. All authors were involved in the decision to submit the article for publication; accordingly, they read and approved the final version of the manuscript. The sponsor was not involved in the collection and interpretation of study data. Study collection and writing the clinical study report were performed by a contract research organization.
    2. de Jong IJ, Eaton A, Bladou F. LHRH agonists in prostate cancer: frequency of treatment, serum Methoctramine measurement and castrate level: consensus opinion from a roundtable discussion. Curr Med Res Opin. 2007;23: 1077e1080.
    4. Mcleod DG. Hormonal therapy: historical perspective to future directions. Urology. 2003;61:3e7.
    5. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132:566e577.
    6. Agarwal DK, Costello AJ, Peters J, Sikaris K, Crowe H. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia. BJU Int. 2000;85:690e695.
    7. Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides. 1999;20:1247e1262.
    8. Limonta P, Montagnani Marelli M, Moretti RM. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs. 2001;10:709e720. 9. Payne H, Mason M. Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent
    12. Chrisp P, Sorkin EM. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging. 1991;1:487e509.
    13. Sharifi R, Soloway M. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group. J Urol. 1990;143: 68e71.
    19. Perez-marreno R, Chu FM, Gleason D, Edward L, Wachs B, Tyler RC. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther. 2002;24:1902e1914.
    21. Marberger M, Kaisary AV, Shore ND, et al. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a phase III, open-label, international multicenter study. Clin Ther. 2010;32:744e757. j.clinthera.2010.04.013.
    23. Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol. 1996;30: 7e14. discussion 19e21.
    25. NCCN. NCCN Clinical Practice Guidelines in Oncology Prostate Cancer Version 2.2017. 2017.
    26. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56:1021 e1024.
    30. Gomella LG. Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev Urol. 2009;11:52e60. https://